Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Alnylam Pharmaceuticals (ALNY) PT Raised to $193 at Stifel Following Results
August 3, 2021 10:51 AM EDTStifel analyst Paul Matteis raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $193.00 (from $178.00) while maintaining a Buy rating following Q2 results.
The analyst commented, "We are reiterating our Buy rating and we're raising our numbers and target price on 2Q beats,... More
Alnylam Pharma (ALNY) Tops Q2 EPS by 30c
August 3, 2021 8:03 AM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.30), $0.30 better than the analyst estimate of ($1.60). Revenue for the quarter came in at $220.1 million versus the consensus estimate of $193.18 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More